Patent · US Active

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

US11813340B2 · kind B2 · utility

1Cited by

2References

31Claims

0Family size

Assignees

THE JOHNS HOPKINS UNIVERSITY · US
Duke University · US

Inventors

Martin G. Pomper · Baltimore, US
Ronnie C. Mease · Fairfax, US
Vivek Kumar · Delhi, IN
Sangeeta Ray · Ellicott City, US
Michael Zalutsky · Chapel Hill, US
Ganesan Vaidyanathan · Flanders, US

Key dates

Filing date	Feb 6, 2019
Grant date	Nov 14, 2023
Priority date	—
Expiry date	Sep 24, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/17021
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.